1,500
Participants
Start Date
July 29, 2022
Primary Completion Date
September 3, 2024
Study Completion Date
September 3, 2024
QIP intervention
"The QIP includes pulmonologist-targeted guideline education and guideline implementation.~Guideline education includes the initial comprehensive training and reinforcement learning. The initial comprehensive education will be delivered at each participating hospital by a dedicated national asthma expert team, immediately after last patient enrolled at each site. The PI of respiratory departments from participating hospitals are responsible for arranging the delivery of hospital-level reinforcement learnings and ensuring the quality and success of hospital-level guideline implementation.~The pulmonologists' guideline adherence and performance at participating hospitals will be regularly assessed during the study period."
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Dalian
Research Site, Changchun
Research Site, Harbin
Research Site, Shanghai
Research Site, Shanghai
Research Site, Kunshan
Research Site, Huai'an
Research Site, Hefei
Research Site, Wuhu
Research Site, Jinan
Research Site, Yantai
Research Site, Tianjin
Research Site, Ningbo
Research Site, Taizhou
Research Site, Jinhua
Research Site, Nanchang
Research Site, Wuyishan
Research Site, Chongqing
Research Site, Changsha
Research Site, Shiyan
Research Site, Hebi
Research Site, Guangzhou
Research Site, Foshan
Research Site, Chengdu
Research Site, Kunming
Research Site, Xi'an
Research Site, Changzhi
Research Site, Handan
Research Site, Nanning
Lead Sponsor
AstraZeneca
INDUSTRY